In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1855 News Items found
Michael Rosensweig with dog
FDA Approves Revumenib, a Menin Inhibitor, for Aggressive Leukemia

Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer carries molecular changes called NPM1 mutations and KMT2A translocations.
Pattie Fuller smiles while wearing a pink plaid poncho
New Treatment for Metastatic (Stage 4) Melanoma: TIL Immunotherapy  

After immunotherapy and targeted therapy failed to bring a patient's melanoma under control, MSK doctors offered her a new treatment called tumor-infiltrating lymphocyte, or TIL, therapy.
Medical oncologist and prostate cancer specialist Dr. Wassim Abida
The Latest on Prostate Cancer Checkpoint Inhibitor Immunotherapy at MSK

Learn how genetic analysis of prostate cancer tumors is guiding treatment with checkpoint inhibitor immunotherapy.
Joey Carlsen Martinez stands smiling in front of a banner that says "Winners Circle"
New Targeted Therapy, Ulixertinib, Shows Promise for Histiocytosis, a Rare Blood Cancer 

Learn how MSK research on a family of rare blood cancers called histiocytosis is leading to new targeted therapies that benefit patients.
A close up of a microscope with two people wearing white coats in the background
ESMO 2025: MSK Presents New Research, Including Latest on Lung and Pancreatic Cancer Treatments

MSK highlights from the recent European Society for Medical Oncology (ESMO) Congress include promising findings on new lung, pancreatic, and colorectal cancer treatments and new insights for how molecular testing can guide personalized medicine.
MSK breast cancer specialist Pedram Razavi, MD, PhD.
Article
Latest Research Into Overcoming Resistance to Breast Cancer Targeted Therapies

Learn how MSK's researchers are making important strides in overcoming breast cancer resistance.
Andy Minn
The Future of Immunotherapy Research at MSK: A Conversation With Dr. Andy Minn, Chair of MSK’s New Immuno-Oncology Program

Dr. Andy Minn, the inaugural chair of MSK's Immuno-Oncology Program, discusses his vision for the program and what it means for patients.
Sara Teichholtz stands in front of the water holding her son.
How Routine Prenatal Tests Can Detect Cancer and What It Means for Pregnant Women 

Learn how noninvasive prenatal tests designed to screen for genetic abnormalities in the fetus may detect the presence of cancer in pregnant women.
MSK computational oncologist Benjamin Greenbaum.
In the Lab
New Research Helps Model How the Immune System Shapes Cancer Development

Read about MSK research that sheds light on how the innate immune system interacts with developing cancer cells.
The co-leaders of the MSK Lobular Breast Cancer program are seen together.
What Is Invasive Lobular Carcinoma? MSK Doctors Explain

Learn about how MSK’s new Lobular Breast Cancer Program is working to improve outcomes for people with invasive lobular breast cancer and other types of LBC.